A formulation containing Curcuma longa (BCM-9) (CURCUGREEN®) and Boswellia serrata (Bospure) extracts was evaluated for safety and efficacy in subjects and directly compared with a selective COX-2 in inhibitor. In total, 54 subjects were screened, 30 subjects were enrolled and 28 completed the study. The treatment was well tolerated and did not produce any adverse effect in subjects, as judged by the vital the of signs, hemogram, liver and renal function tests.
The formulation at 500 mg administered twice a day, was more successful than in administration of the COX-2 inhibitor in (100 mg twice a day) for symptom scorin and clinical examination.The formulatio was found to be safe and no dose-related toxicity was found.
We have received your message and will get in touch with you shortly
We Have Received Your Query and will connect on your mail Id soon with all the details
Your sign-up request was successful! Please check your email inbox to confirm.